Krebs, Mark R. H.,Dai, David,Sule, Shantanu,Rabah, Dania,Martin, David
申请号：
AU2017258191
公开号：
AU2017258191A1
申请日:
2017.04.27
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the treatment of BDCA2 -associated disorders such as systematic lupus erythematosus, cutaneous lupus eiythernatosus, and discoid lupus erythematosus, and cytokine release syndrome.
